Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports
03/07/2025 15:34
July 3 (Reuters) - Summit Therapeutics SMMT.O is considering an up to $15 billion partnership with AstraZeneca AZN.L, Bloomberg News reported on Thursday, citing people familiar with the matter. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)